A complex mutational signature generated by cytarabine resistance
NAR Cancer · 27.07.2026 · 8 (3)
DOI: 10.1093/narcan/zcag017 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 21.08.2026. Verfasst von Dengchao Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Hauptthemen laut MEDLINE: Cytarabine, Drug Resistance, Neoplasm, Mutation, Antimetabolites, Antineoplastic. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
T-cell acute lymphoblastic leukemia (T-ALL) patients generally respond well to chemotherapy, but T-ALL cells at relapse are typically resistant to chemotherapy. The specific mechanisms leading to chemoresistance are incompletely understood. We used Mcm2 hypomorph T-ALL cell lines, which are prone to copy number variant mutations, to identify acquired mutations that underlie chemoresistance. We found acquired copy number variants leading to resistance to a wide spectrum of chemotherapeutic agents and focused on cell lines that inactivated both Dck and Trp53, leading to cytarabine resistance and a unique mutational signature. This signature is characterized by C > T mutations in a GCG trinucleotide context, T > C in a GTC context, T > G in GTC and GTT contexts, and C > G in a GCC context. Ongoing cytarabine exposure is not required for this mutational signature. Further analyses revealed that the T > C in GTC context is associated with proliferation rate, while the C > G in GCC context is associated with Trp53 mutations. These findings provide new insight into the genetic evolution of chemoresistance, add to emerging evidence that chemotherapeutic agents can produce characteristic mutational signatures, and demonstrate that mutagenic effects of chemotherapy can be indirect, acting through selection of clones with distinct mutation profiles and a resultant mutator phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
- Department of Biomedical Sciences, The School of Veterinary Medicine, The University of Pennsylvania, Philadelphia, PA 19104, United States.
- Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD 20892, United States.
ORCID-Profile: Dengchao Cao, Mianmian Yin, Paul Meltzer, Peter D Aplan
Förderung
- Intramural NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Cao, D., Yin, M., Bertoli, R., Zhang, Z., Lu, A., Zhu, J., Baslan, T., Chung, Y. J., Negi, V., Meltzer, P., & Aplan, P. D. (2026). A complex mutational signature generated by cytarabine resistance. NAR Cancer, 8(3). https://doi.org/10.1093/narcan/zcag017
Vancouver
Cao D, Yin M, Bertoli R, Zhang Z, Lu A, Zhu J, et al. A complex mutational signature generated by cytarabine resistance. NAR Cancer. 2026;8(3). doi:10.1093/narcan/zcag017
BibTeX
@article{Cao2026,
author = {Cao, Dengchao and Yin, Mianmian and Bertoli, Ryan and Zhang, Zhenhua and Lu, Allyson and Zhu, Jack and Baslan, Timour and Chung, Yang Jo and Negi, Vijay and Meltzer, Paul and Aplan, Peter D},
title = {A complex mutational signature generated by cytarabine resistance},
journal = {NAR Cancer},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/narcan/zcag017}
}
EUVIMED